Full Press Release Details
| For investors | For media | |
| Amy Wakeham | Jayme Rubenstein | |
| +1 858-836-5000 | +1 858-836-6798 | |
| investorrelations@resmed.com | news@resmed.com |
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2020
Year-over-year revenue grows 9%, non-GAAP operating profit up
Note: A webcast of ResMed s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
SAN DIEGO, August 5, 2020 ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading digital health company, today announced results for its quarter ended
Fourth Quarter 2020 Highlights
All comparisons are to the prior year period
Full Year 2020 Highlights
All comparisons are to the prior year period
Our fourth quarter results reflect the strength and resiliency of our business in today s uncertain
environment. We finished fiscal year 2020 with double-digit revenue growth to $3.0 billion and operating profit up 24% on a non-GAAP basis, said Mick Farrell, ResMed s CEO. Throughout our
fiscal fourth quarter, we continued to support the COVID-19 pandemic response through increased manufacturing of our ventilators, including bilevels, and ventilation mask systems while also supporting our
customers with digital health solutions and other innovative tools to enable remote care for patients. Looking ahead, we are confident in our ability to navigate through the ongoing challenging clinical and economic environment to deliver for all
our stakeholders. Sleep labs and physician practices are reopening across many geographies, and we re seeing accelerated adoption of digital health solutions which supports our long-term strategy. We remain vigilant and thoughtful about the
outlook for our business as we continue to serve our customers, and we believe our strong foundation will accelerate our growth over the longer term.
Financial Results and Operating Metrics
Unaudited; $ in millions, except for per share amounts
| Three Months Ended | ||||||||||||||||
| June 30, 2020 | June 30, 2019 | % Change | Constant Currency (A) | |||||||||||||
| Revenue | $ | 770.3 | $ | 705.0 | 9 | % | 10 | % | ||||||||
| Gross margin (B) | 58.3 | % | 57.1 | % | 2 | |||||||||||
| Non-GAAP gross margin (B) | 59.9 | % | 59.3 | % | 1 | |||||||||||
| Selling, general and administrative expenses | 165.4 | 171.6 | (4 | ) | 0 | |||||||||||
| Research and development expenses | 52.5 | 51.1 | 3 | 4 | ||||||||||||
| Income from operations | 223.2 | 121.1 | 84 | |||||||||||||
| Non-GAAP income from operations (B) | 243.4 | 196.2 | 24 | |||||||||||||
| Net income | 177.8 | 68.8 | 158 | |||||||||||||
| Non-GAAP net income (B) | 193.3 | 137.6 | 40 | |||||||||||||
| Diluted earnings per share | $ | 1.22 | $ | 0.48 | 154 | |||||||||||
| Non-GAAP diluted earnings per share (B) | $ | 1.33 | $ | 0.95 | 40 | |||||||||||
| Twelve Months Ended | ||||||||||||||||
| June 30, 2020 | June 30, 2019 | % Change | Constant Currency (A) | |||||||||||||
| Revenue | $ | 2,957.0 | $ | 2,606.6 | 13 | % | 15 | % | ||||||||
| Gross margin (B) | 58.1 | % | 57.3 | % | 1 | |||||||||||
| Non-GAAP gross margin (B) | 59.8 | % | 59.0 | % | 1 | |||||||||||
| Selling, general and administrative expenses | 676.7 | 645.0 | 5 | 7 | ||||||||||||
| Research and development expenses | 201.9 | 180.7 | 12 | 14 | ||||||||||||
| Income from operations | 809.7 | 579.3 | 40 | |||||||||||||
| Non-GAAP income from operations (B) | 890.9 | 716.3 | 24 | |||||||||||||
| Net income | 621.7 | 404.6 | 54 | |||||||||||||
| Non-GAAP net income (B) | 692.8 | 526.4 | 32 | |||||||||||||
| Diluted earnings per share | $ | 4.27 | $ | 2.80 | 53 | |||||||||||
| Non-GAAP diluted earnings per share (B) | $ | 4.76 | $ | 3.64 | 31 |
Discussion of Fourth Quarter Results
All comparisons are to the prior year period unless otherwise noted
Other Business and Operational Highlights
The ResMed board of directors today declared a quarterly cash dividend of $0.39 per share. The dividend will have a record date of August 20, 2020,
payable on September 24, 2020. The dividend will be paid in U.S. currency to holders of ResMed s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests ( CDIs ) trading on the Australian
Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date
will be August 19, 2020, for common stockholders and for CDI holders. ResMed has received a waiver from the ASX s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI
registers from August 19, 2020, through August 20, 2020, inclusive.
ResMed will discuss its fourth quarter fiscal year 2020 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be
accessed on ResMed s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the Q4 2020 Earnings Webcast to register and listen to the live webcast. A replay of
the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately two hours after the webcast by dialing +1 833-241-4253 (U.S.) or +1 647-689-4204 (outside U.S.) and entering the passcode 2498310. The
telephone replay will be available until August 19, 2020.
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier,
higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive
out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better
care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
Safe harbor statement
Statements contained in
this release that are not historical facts are forward-looking statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements including statements regarding ResMed s
projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, litigation, and tax outlook are subject to risks and uncertainties, which could
cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed s periodic reports on file with the U.S. Securities & Exchange
Commission. ResMed does not undertake to update its forward-looking statements.
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Income
(Unaudited; $ in thousands, except for per share amounts)
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| June 30, 2020 | June 30, 2019 | June 30, 2020 | June 30, 2019 | |||||||||||||
| Net revenue | $ | 770,343 | $ | 704,964 | $ | 2,957,013 | $ | 2,606,572 | ||||||||
| Cost of sales | 308,991 | 287,114 | 1,189,624 | 1,069,987 | ||||||||||||
| Amortization of acquired intangibles (1) | 11,980 | 15,418 | 49,603 | 42,514 | ||||||||||||
| Total cost of sales | $ | 320,971 | $ | 302,532 | $ | 1,239,227 | $ | 1,112,501 | ||||||||
| Gross profit | $ | 449,372 | $ | 402,432 | $ | 1,717,786 | $ | 1,494,071 | ||||||||
| Selling, general and administrative | 165,385 | 171,600 | 676,689 | 645,010 | ||||||||||||
| Research and development | 52,520 | 51,138 | 201,946 | 180,651 | ||||||||||||
| Amortization of acquired intangibles (1) | 8,220 | 8,019 | 30,092 | 32,424 | ||||||||||||
| Restructuring expenses (1) | 9,401 | 9,401 | ||||||||||||||
| Litigation settlement expenses (1) | 41,199 | (600 | ) | 41,199 | ||||||||||||
| Acquisition-related expenses (1) | 6,123 | |||||||||||||||
| Total operating expenses | $ | 226,125 | $ | 281,357 | $ | 908,127 | $ | 914,808 | ||||||||
| Income from operations | 223,247 | 121,075 | 809,659 | 579,263 | ||||||||||||
| Other income (expenses), net: | ||||||||||||||||
| Interest income (expense), net | $ | (8,942 | ) | $ | (12,264 | ) | $ | (39,356 | ) | $ | (33,857 | ) | ||||
| Loss attributable to equity method investments | (5,976 | ) | (6,463 | ) | (25,058 | ) | (15,833 | ) | ||||||||
| Other, net | 3,765 | (6,587 | ) | (12,157 | ) | (10,726 | ) | |||||||||
| Total other income (expenses), net | (11,153 | ) | (25,314 | ) | (76,571 | ) | (60,416 | ) | ||||||||
| Income before income taxes | $ | 212,094 | $ | 95,761 | $ | 733,088 | $ | 518,847 | ||||||||
| Income taxes | 34,259 | 26,964 | 111,414 | 114,255 | ||||||||||||
| Net income | $ | 177,835 | $ | 68,797 | $ | 621,674 | $ | 404,592 | ||||||||
| Basic earnings per share | $ | 1.23 | $ | 0.48 | $ | 4.31 | $ | 2.83 | ||||||||
| Diluted earnings per share | $ | 1.22 | $ | 0.48 | $ | 4.27 | $ | 2.80 | ||||||||
| Non-GAAP diluted earnings per share (1) | $ | 1.33 | $ | 0.95 | $ | 4.76 | $ | 3.64 | ||||||||
| Basic shares outstanding | 144,792 | 143,435 | 144,338 | 143,111 | ||||||||||||
| Diluted shares outstanding | 145,866 | 144,687 | 145,652 | 144,484 |
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
| June 30, 2020 | June 30, 2019 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 463,156 | $ | 147,128 | ||||
| Accounts receivable, net | 474,643 | 528,484 | ||||||
| Inventories | 416,915 | 349,641 | ||||||
| Prepayments and other current assets | 168,745 | 120,113 | ||||||
| Total current assets | $ | 1,523,459 | $ | 1,145,366 | ||||
| Non-current assets: | ||||||||
| Property, plant and equipment, net | $ | 417,335 | $ | 387,460 | ||||
| Operating lease right-of-use assets | 118,348 | |||||||
| Goodwill and other intangibles, net | 2,338,492 | 2,378,399 | ||||||
| Deferred income taxes and other non-current assets | 189,742 | 196,457 | ||||||
| Total non-current assets | $ | 3,063,917 | $ | 2,962,316 | ||||
| Total assets | $ | 4,587,376 | $ | 4,107,682 | ||||
| LIABILITIES AND STOCKHOLDERS EQUITY: | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 135,786 | $ | 115,725 | ||||
| Accrued expenses | 270,353 | 266,359 | ||||||
| Operating lease liabilities, current | 21,263 | |||||||
| Deferred revenue | 98,617 | 88,667 | ||||||
| Income taxes payable | 64,755 | 73,248 | ||||||
| Short-term debt | 11,987 | 11,992 | ||||||
| Total current liabilities | $ | 602,761 | $ | 555,991 | ||||
| Non-current liabilities: | ||||||||
| Deferred revenue | $ | 87,307 | $ | 81,143 | ||||
| Deferred income taxes | 13,011 | 11,380 | ||||||
| Operating lease liabilities, non-current | 101,880 | |||||||
| Other long term liabilities | 8,347 | 2,058 | ||||||
| Long-term debt | 1,164,133 | 1,258,861 | ||||||
| Long-term income taxes payable | 112,910 | 126,056 | ||||||
| Total non-current liabilities | $ | 1,487,588 | $ | 1,479,498 | ||||
| Total liabilities | $ | 2,090,349 | $ | 2,035,489 | ||||
| STOCKHOLDERS EQUITY: | ||||||||
| Common stock | $ | 580 | $ | 575 | ||||
| Additional paid-in capital | 1,570,694 | 1,511,473 | ||||||
| Retained earnings | 2,832,991 | 2,436,410 | ||||||
| Treasury stock | (1,623,256 | ) | (1,623,256 | ) | ||||
| Accumulated other comprehensive income | (283,982 | ) | (253,009 | ) | ||||
| Total stockholders equity | $ | 2,497,027 | $ | 2,072,193 | ||||
| Total liabilities and stockholders equity | $ | 4,587,376 | $ | 4,107,682 |
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited; $ in thousands)
| Twelve Months Ended | ||||||||
| June 30, 2020 | June 30, 2019 | |||||||
| Cash flows from operating activities: | ||||||||
| Net income | $ | 621,674 | $ | 404,592 | ||||
| Adjustment to reconcile net income to cash provided by operating activities: | ||||||||
| Depreciation and amortization | 154,850 | 150,795 | ||||||
| Amortization of right-of-use-assets | 26,523 | |||||||
| Stock-based compensation costs | 57,559 | 52,073 | ||||||
| Loss attributable to equity method investments | 25,058 | 15,833 | ||||||
| Impairment of equity investments | 14,519 | 15,007 | ||||||
| Gain on previously held equity interest | (1,909 | ) | ||||||
| Changes in fair value of business combination contingent consideration | (7 | ) | (286 | ) | ||||
| Changes in operating assets and liabilities, net of effect of acquisitions: | ||||||||
| Accounts receivable, net | 54,383 | (18,013 | ) | |||||
| Inventories, net | (69,881 | ) | (84,188 | ) | ||||
| Prepaid expenses, net deferred income taxes and other current assets | (58,999 | ) | (47,575 | ) | ||||
| Accounts payable, accrued expenses and other | (23,424 | ) | (27,278 | ) | ||||
| Net cash provided by operating activities | $ | 802,255 | $ | 459,051 | ||||
| Cash flows from investing activities: | ||||||||
| Purchases of property, plant and equipment | (95,330 | ) | (68,710 | ) | ||||
| Patent registration costs | (10,608 | ) | (8,632 | ) | ||||
| Business acquisitions, net of cash acquired | (27,910 | ) | (951,383 | ) | ||||
| Purchases of investments | (31,616 | ) | (46,717 | ) | ||||
| Proceeds / (Payments) on maturity of foreign currency contracts | (14,397 | ) | (264 | ) | ||||
| Net cash used in investing activities | $ | (179,861 | ) | $ | (1,075,706 | ) | ||
| Cash flows from financing activities: | ||||||||
| Proceeds from issuance of common stock, net | 48,182 | 36,727 | ||||||
| Taxes paid related to net share settlement of equity awards | (46,061 | ) | (28,104 | ) | ||||
| Purchases of treasury stock | (22,844 | ) | ||||||
| Payment of business combination contingent consideration | (302 | ) | (909 | ) | ||||
| Proceeds from borrowings, net of borrowing costs | 1,190,000 | 1,519,230 | ||||||
| Repayment of borrowings | (1,284,012 | ) | (711,745 | ) | ||||
| Dividends paid | (225,093 | ) | (211,712 | ) | ||||
| Net cash (used in) / provided by financing activities | $ | (317,286 | ) | $ | 580,643 | |||
| Effect of exchange rate changes on cash | $ | 10,920 | $ | (5,561 | ) | |||
| Net increase / (decrease) in cash and cash equivalents | 316,028 | (41,573 | ) | |||||
| Cash and cash equivalents at beginning of period | 147,128 | 188,701 | ||||||
| Cash and cash equivalents at end of period | $ | 463,156 | $ | 147,128 |
RESMED INC. AND SUBSIDIARIES
Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)
The measures non-GAAP gross profit and non-GAAP gross
margin excludes amortization expense from acquired intangibles related to cost of sales and are reconciled below:
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| June 30, 2020 | June 30, 2019 | June 30, 2020 | June 30, 2019 | |||||||||||||
| Revenue | $ | 770,343 | $ | 704,964 | $ | 2,957,013 | $ | 2,606,572 | ||||||||
| Add back: Deferred revenue fair value adjustment (A) | 1,065 | 2,102 | 5,348 | |||||||||||||
| Non-GAAP Revenue | $ | 770,343 | $ | 706,029 | $ | 2,959,115 | $ | 2,611,920 | ||||||||
| GAAP Cost of sales | $ | 320,971 | $ | 302,532 | $ | 1,239,227 | $ | 1,112,501 | ||||||||
| Less: Amortization of acquired intangibles (A) | (11,980 | ) | (15,418 | ) | (49,603 | ) | (42,514 | ) | ||||||||
| Non-GAAP cost of sales | $ | 308,991 | $ | 287,114 | $ | 1,189,624 | $ | 1,069,987 | ||||||||
| GAAP gross profit | 449,372 | 402,432 | 1,717,786 | 1,494,071 | ||||||||||||
| GAAP gross margin | 58.3 | % | 57.1 | % | 58.1 | % | 57.3 | % | ||||||||
| Non-GAAP gross profit | 461,352 | 418,915 | 1,769,491 | 1,541,933 | ||||||||||||
| Non-GAAP gross margin | 59.9 | % | 59.3 | % | 59.8 | % | 59.0 | % |
The measure non-GAAP income from operations is reconciled with GAAP income
from operations below:
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| June 30, 2020 | June 30, 2019 | June 30, 2020 | June 30, 2019 | |||||||||||||
| GAAP income from operations | $ | 223,247 | $ | 121,075 | $ | 809,659 | $ | 579,263 | ||||||||
| Amortization of acquired intangibles - cost of sales (A) | 11,980 | 15,418 | 49,603 | 42,514 | ||||||||||||
| Amortization of acquired intangibles - operating expenses (A) | 8,220 | 8,019 | 30,092 | 32,424 | ||||||||||||
| Deferred revenue fair value adjustment (A) | 1,065 | 2,102 | 5,348 | |||||||||||||
| Restructuring expenses (A) | 9,401 | 9,401 | ||||||||||||||
| Litigation settlement expenses (A) | 41,199 | (600 | ) | 41,199 | ||||||||||||
| Acquisition related expenses (A) | 6,123 | |||||||||||||||
| Non-GAAP income from operations | $ | 243,447 | $ | 196,177 | $ | 890,856 | $ | 716,272 |
RESMED INC. AND SUBSIDIARIES
Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)
The measures non-GAAP net income and non-GAAP diluted
earnings per share are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| June 30, 2020 | June 30, 2019 | June 30, 2020 | June 30, 2019 | |||||||||||||
| GAAP net income | $ | 177,835 | $ | 68,797 | $ | 621,674 | $ | 404,592 | ||||||||
| Amortization of acquired intangibles - cost of sales, net of tax (A) | 9,167 | 11,447 | 37,933 | 32,477 | ||||||||||||
| Amortization of acquired intangibles - operating expenses, net of tax (A) | 6,290 | 5,954 | 23,012 | 24,769 | ||||||||||||
| Deferred revenue fair value adjustment, net of tax (A) | 786 | 1,610 | 4,067 | |||||||||||||
| Restructuring expenses, net of tax (A) | 7,205 | 7,205 | ||||||||||||||
| Litigation settlement expenses, net of tax (A) | 36,248 | (528 | ) | 36,248 | ||||||||||||
| Fair value impairment of investment (A) | 5,000 | 9,100 | 5,000 | |||||||||||||
| U.S. tax reform | 2,149 | 6,654 | ||||||||||||||
| Acquisition-related expenses (A) | 5,362 | |||||||||||||||
| Non-GAAP net income (A) | $ | 193,292 | $ | 137,586 | $ | 692,801 | $ | 526,374 | ||||||||
| Diluted shares outstanding | 145,866 | 144,687 | 145,652 | 144,484 | ||||||||||||
| GAAP diluted earnings per share | $ | 1.22 | $ | 0.48 | $ | 4.27 | $ | 2.80 | ||||||||
| Non-GAAP diluted earnings per share (A) | $ | 1.33 | $ | 0.95 | $ | 4.76 | $ | 3.64 |
ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that
investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period
and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.
RESMED INC. AND SUBSIDIARIES
Revenue by Product and Region
millions, except for per share amounts)
| Three Months Ended | ||||||||||||||||
| June 30, 2020 (A) | June 30, 2019 (A) | % Change | Constant Currency (B) | |||||||||||||
| U.S., Canada and Latin America | ||||||||||||||||
| Devices | $ | 205.9 | $ | 202.9 | 1 | % | ||||||||||
| Masks and other | 194.7 | 182.6 | 7 | |||||||||||||
| Total Sleep and Respiratory Care | $ | 400.5 | $ | 385.5 | 4 | |||||||||||
| Software as a Service | 91.5 | 85.2 | 7 | |||||||||||||
| Total | $ | 492.0 | $ | 470.7 | 5 | |||||||||||
| Combined Europe, Asia and other markets | ||||||||||||||||
| Devices | $ | 205.8 | $ | 155.5 | 32 | % | 35 | % | ||||||||
| Masks and other | 72.6 | 78.8 | -8 | -6 | ||||||||||||
| Total Sleep and Respiratory Care | $ | 278.3 | $ | 234.3 | 19 | 22 | ||||||||||
| Global revenue | ||||||||||||||||
| Devices | $ | 411.6 | $ | 358.4 | 15 | % | 16 | % | ||||||||
| Masks and other | 267.2 | 261.4 | 2 | 3 | ||||||||||||
| Total Sleep and Respiratory Care | $ | 678.9 | $ | 619.8 | 10 | 11 | ||||||||||
| Software as a Service | 91.5 | 85.2 | 7 | 7 | ||||||||||||
| Total | $ | 770.3 | $ | 705.0 | 9 | 10 | ||||||||||
| Twelve Months Ended | ||||||||||||||||
| June 30, 2020 (A) | June 30, 2019 (A) | % Change | Constant Currency (B) | |||||||||||||
| U.S., Canada and Latin America | ||||||||||||||||
| Devices | $ | 792.8 | $ | 743.1 | 7 | % | ||||||||||
| Masks and other | 779.6 | 677.4 | 15 | |||||||||||||
| Total Sleep and Respiratory Care | $ | 1,572.3 | $ | 1,420.5 | 11 | |||||||||||
| Software as a Service | 354.6 | 275.8 | 29 | |||||||||||||
| Total | $ | 1,927.0 | $ | 1,696.3 | 14 | |||||||||||
| Combined Europe, Asia and other markets | ||||||||||||||||
| Devices | $ | 715.1 | $ | 618.5 | 16 | % | 19 | % | ||||||||
| Masks and other | 315.0 | 291.8 | 8 | 11 | ||||||||||||
| Total Sleep and Respiratory Care | $ | 1,030.1 | $ | 910.3 | 13 | 16 | ||||||||||
| Global revenue | ||||||||||||||||
| Devices | $ | 1,507.8 | $ | 1,361.6 | 11 | % | 12 | % | ||||||||
| Masks and other | 1,094.6 | 969.2 | 13 | 14 | ||||||||||||
| Total Sleep and Respiratory Care | $ | 2,602.4 | $ | 2,330.8 | 12 | 13 | ||||||||||
| Software as a Service | 354.6 | 275.8 | 29 | 29 | ||||||||||||
| Total | $ | 2,957.0 | $ | 2,606.6 | 13 | 15 |